Trade names Voquezna
Routes of administration by mouth
Drug class Potassium-competitive acid blocker
Bioavailability unknown
Protein binding 80%
Metabolism Liver, by cytochrome P450 (3A4, 2B6, 2C19, 2D6)
Elimination half-life 7.7 h
Duration of action > 24 h
Excretion Kidney
A first-in-class potassium-competitive acid blocker medication.
Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcers and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.
Co-packaged combinations of vonoprazan with amoxicillin and vonoprazan with amoxicillin and clarithromycin are available.
Vonoprazan is indicated for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults; to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults; in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection in adults; in combination with amoxicillin for the treatment of H. pylori infection in adults; non-erosive gastroesophageal reflux disease.
The most common side effects are constipation, diarrhea, enlarged feeling of abdomen, nausea, rash, and edema.
Long-term use may lead to vitamin B12 deficiency, hypomagnesemia, and fundic gland polyps.